Agios Pharmaceuticals
AGIO
168 hedge funds and large institutions have $1.64B invested in Agios Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 57 increasing their positions, 50 reducing their positions, and 23 closing their positions.
57% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 23
26% more capital invested
Capital invested by funds: $1.3B → $1.64B (+$333M)
14% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 50
8% more funds holding
Funds holding: 155 → 168 (+13)
1.84% less ownership
Funds ownership: 107.58% → 105.74% (-1.8%)
44% less call options, than puts
Call options by funds: $10.6M | Put options by funds: $18.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$51.6M |
| 2 |
Fisher Asset Management
Camas,
Washington
|
+$22.5M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$20.8M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$6.88M |
| 5 |
Axa
Paris,
France
|
+$4.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
-$36.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$28.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$27.6M |
| 4 |
State Street
Boston,
Massachusetts
|
-$20.6M |
| 5 |
CC
Casdin Capital
New York
|
-$17.4M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$4K | -196 | Closed |
|
|
LSA
177
Leonteq Securities AG
Zurich,
Switzerland
| – | -$3.06K | -138 | Closed |
|
178
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
| – | -$3K | -121 | Closed |
|
179
Rockefeller Capital Management
New York
| – | -$2K | -118 | Closed |
|
|
SWM
180
Spire Wealth Management
Mclean,
Virginia
| – | -$1K | -45 | Closed |
|
|
SIC
181
SJS Investment Consulting
Sylvania,
Ohio
| – | +$27 | +1 | New |
|
|
TWA
182
TCI Wealth Advisors
Tucson,
Arizona
| – | +$27 | +1 | New |
|
|
JWA
183
JFS Wealth Advisors
Hermitage,
Pennsylvania
| – | +$107 | +4 | +100% |
|
|
PA
184
Parallel Advisors
San Francisco,
California
| – | +$107 | +4 | New |
|
|
C
185
Covestor
London,
United Kingdom
| – | +$188 | +7 | New |
|
|
EI
186
Ellevest Inc
New York
| – | +$215 | +8 | New |
|
AGIO Hedge Fund Activity: Q3 2022 in Review
168 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q3 2022, worth a combined $1.64B — up 26% from $1.3B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new AGIO positions and 23 closed out — a net gain of 13 holders — while 57 added to existing stakes and 50 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $51.6M. The largest seller was Suvretta Capital Management, cutting an estimated $36.5M.
- 168 institutional investors held Agios Pharmaceuticals (AGIO) as of Q3 2022, up from 155 in Q2 2022.
- Funds reported $1.64B of Agios Pharmaceuticals stock for Q3 2022, up 26% quarter-over-quarter.
- 36 funds opened new Agios Pharmaceuticals positions in Q3 2022 and 23 closed out, a net change of +13 holders.
- The largest Agios Pharmaceuticals buyer in Q3 2022 was Armistice Capital, an estimated $51.6M added.
- The largest Agios Pharmaceuticals seller in Q3 2022 was Suvretta Capital Management, an estimated $36.5M sold.
Based on aggregated 13F filings for Q3 2022.